Login / Signup

Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.

Andrés Muñoz MartinEnrique GallardoGiancarlo AgnelliCarlos CrespoMonica ForghaniDaniel ArumiSusana Fernández de CaboJavier Soto
Published in: Journal of medical economics (2022)
Our results suggest that DOAC is cost-effective and cost-saving compared to LMWH in treating VTE.
Keyphrases
  • venous thromboembolism
  • direct oral anticoagulants
  • atrial fibrillation
  • combination therapy
  • replacement therapy
  • smoking cessation